Physician
North Clark Medical Group LLC
North Clark Medical Group LLC was paid $16.17M by Medicaid between Jan 2018 and Dec 2024, across 136 billing codes. Its largest line is 99213, doctor's office visit, returning patient (routine) — 30% of everything it billed.
33Billing provider infoNORTH CLARK MEDICAL GROUP LLC
JEFFERSONVILLE, IN 47130
JEFFERSONVILLE, IN 47130
33aNPI1376095711assigned 11/02/2016
33bProvider typeAddiction Medicine (Internal Medicine) Physician
28Total paid$16.17M
24GClaims730,971
24DCodes billed136
24AFirst – last monthJan 2018 – Dec 2024
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 91,291 | $842K | |
| 2019 | 136,340 | $1.94M | |
| 2020 | 155,168 | $2.32M | |
| 2021 | 148,915 | $2.56M | |
| 2022 | 67,020 | $2.28M | |
| 2023 | 69,675 | $2.89M | |
| 2024incomplete | 62,562 | $3.34M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99213 | Doctor's office visit, returning patient (routine)Office or other outpatient visit for the evaluation and management of an established patient, low complexity | 30% | 106,589 | 72,981 | $4.77M |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | 23% | 100,724 | 60,231 | $3.77M |
| H0020 | Alcohol and/or drug services; methadone administration and/or service (provision of the drug by a licensed program) | 13% | 20,529 | 5,681 | $2.13M |
| 99214 | Doctor's office visit, returning patient (more involved)Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity | 5.2% | 14,733 | 11,198 | $839K |
| 90837 | Psychotherapy session, about an hourPsychotherapy, 53 minutes with patient | 2.7% | 5,522 | 3,276 | $444K |
| G0481 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 8-14 drug class(es), including metabolite(s) if performed | 2.7% | 3,538 | 2,713 | $435K |
| 90853 | Group psychotherapy (other than of a multiple-family group) | 2.4% | 23,940 | 13,568 | $385K |
| G0483 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 22 or more drug class(es), including metabolite(s) if performed | 1.6% | 7,750 | 5,538 | $262K |
| T2023 | Targeted case management; per month | 1.6% | 907 | 763 | $255K |
| 99203 | Doctor's office visit, new patient (routine)Office or other outpatient visit for the evaluation and management of a new patient, low complexity | 1.2% | 3,467 | 2,860 | $188K |
| 80050 | General health panel | <1% | 4,053 | 3,413 | $157K |
| 80365 | <1% | 9,356 | 6,430 | $117K |
124 more codes
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 6,989 | $108K |
| 80373 | <1% | 9,336 | $98K | |
| 83992 | <1% | 9,335 | $81K | |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 1,873 | $63K |
| 80346 | <1% | 10,020 | $60K | |
| H0016 | Alcohol and/or drug services; medical/somatic (medical intervention in ambulatory setting) | <1% | 321 | $60K |
| 80369 | <1% | 9,337 | $57K | |
| 80350 | <1% | 9,360 | $57K | |
| 80348 | <1% | 9,599 | $57K | |
| 80354 | <1% | 9,335 | $56K | |
| 90834 | Psychotherapy session, about 45 minutes | <1% | 1,127 | $55K |
| 82607 | <1% | 6,709 | $53K | |
| 87633 | Infectious agent detection by nucleic acid, respiratory virus, 12-25 targets | <1% | 323 | $51K |
| 80061 | Lipid panel | <1% | 7,469 | $51K |
| 80358 | <1% | 10,014 | $50K | |
| 80355 | <1% | 9,438 | $50K | |
| 82746 | <1% | 6,406 | $49K | |
| 84480 | <1% | 7,081 | $49K | |
| 81003 | <1% | 48,098 | $48K | |
| 80361 | <1% | 9,555 | $47K | |
| 80372 | <1% | 9,336 | $47K | |
| 80333 | <1% | 9,335 | $46K | |
| 80337 | <1% | 9,336 | $46K | |
| G2023 | Specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | <1% | 2,848 | $43K |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 7,701 | $42K |
| 80368 | <1% | 9,335 | $42K | |
| 80359 | <1% | 9,334 | $41K | |
| 80356 | <1% | 10,007 | $41K | |
| 80363 | <1% | 9,392 | $41K | |
| 80324 | <1% | 9,549 | $40K | |
| 99204 | Doctor's office visit, new patient (more involved) | <1% | 597 | $39K |
| 99212 | Office or other outpatient visit for the evaluation and management of an established patient, straightforward | <1% | 1,621 | $38K |
| 80345 | <1% | 9,336 | $34K | |
| 86769 | <1% | 1,149 | $34K | |
| 80366 | <1% | 9,335 | $32K | |
| 84439 | <1% | 7,054 | $32K | |
| 80349 | <1% | 9,560 | $32K | |
| H0038 | Self-help/peer services, per 15 minutes | <1% | 1,480 | $32K |
| 80353 | <1% | 9,336 | $28K | |
| 80360 | <1% | 9,335 | $28K | |
| 80323 | <1% | 9,325 | $28K | |
| 80371 | <1% | 9,335 | $28K | |
| 84403 | <1% | 2,260 | $27K | |
| H0032 | Mental health service plan development by non-physician | <1% | 500 | $25K |
| 80074 | <1% | 836 | $25K | |
| H0001 | Alcohol and/or drug assessment | <1% | 321 | $24K |
| 83735 | <1% | 6,296 | $22K | |
| 96127 | <1% | 9,221 | $22K | |
| 83540 | <1% | 6,422 | $22K | |
| 90791 | Psychiatric diagnostic evaluation | <1% | 182 | $19K |
| G0482 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 15-21 drug class(es), including metabolite(s) if performed | <1% | 525 | $19K |
| 90838 | <1% | 243 | $14K | |
| 84550 | <1% | 6,110 | $14K | |
| 99202 | Office or other outpatient visit for the evaluation and management of a new patient, straightforward | <1% | 355 | $13K |
| 87389 | Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies | <1% | 679 | $11K |
| 99215 | Doctor's office visit, returning patient (complex) | <1% | 68 | $11K |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 1,417 | $11K |
| 99417 | Prolong home eval add 15m | <1% | 68 | $10K |
| 86696 | <1% | 659 | $8K | |
| 0202U | Oncology (prostate), multianalyte, gene expression profiling | <1% | 57 | $8K |
| 86645 | <1% | 676 | $7K | |
| 90832 | Psychotherapy session, about 30 minutes | <1% | 185 | $7K |
| 86644 | <1% | 676 | $6K | |
| 80305 | <1% | 661 | $6K | |
| 80053 | Comprehensive metabolic panel | <1% | 1,809 | $6K |
| 90792 | Psychiatric diagnostic evaluation with medical services | <1% | 54 | $6K |
| 86695 | <1% | 658 | $6K | |
| 00630 | <1% | 110 | $5K | |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 2,022 | $5K |
| 87631 | <1% | 139 | $5K | |
| 99406 | <1% | 455 | $5K | |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 1,174 | $4K |
| 82570 | <1% | 789 | $2K | |
| 82728 | <1% | 343 | $2K | |
| 87637 | Infectious agent detection by nucleic acid; SARS-CoV-2, influenza, and RSV | <1% | 15 | $2K |
| 84466 | <1% | 293 | $2K | |
| 86592 | <1% | 677 | $2K | |
| 64493 | <1% | 22 | $2K | |
| 99205 | Prolong outpt/office vis | <1% | 70 | $2K |
| 99490 | Ccm add 20min | <1% | 602 | $1K |
| 80367 | <1% | 1,984 | $1K | |
| 99211 | Office or other outpatient visit for the evaluation and management of an established patient, minimal severity | <1% | 362 | $1K |
| 90632 | <1% | 51 | $1K | |
| G0444 | Annual depression screening, 5 to 15 minutes | <1% | 243 | $1K |
| 64494 | <1% | 22 | $919.77 | |
| 81002 | <1% | 1,131 | $911.42 | |
| H0002 | Behavioral health screening to determine eligibility for admission to treatment program | <1% | 20 | $886.78 |
| G0442 | Annual alcohol misuse screening, 5 to 15 minutes | <1% | 239 | $849.98 |
| 86580 | <1% | 253 | $840.58 | |
| 36415 | Collection of venous blood by venipuncture | <1% | 721 | $665.49 |
| 99050 | <1% | 1,245 | $646.68 | |
| 71046 | Radiologic examination, chest; 2 views | <1% | 37 | $592.19 |
| 82947 | <1% | 319 | $589.40 | |
| 90674 | <1% | 18 | $497.26 | |
| 72100 | <1% | 40 | $471.11 | |
| 99072 | <1% | 13,945 | $459.48 | |
| G2067 | Medication assisted treatment, methadone; weekly bundle including dispensing and/or administration, substance use counseling, individual and group therapy, and toxicology testing, if performed (provision of the services by a medicare-enrolled opioid treatment program) | <1% | 304 | $394.64 |
| 99348 | <1% | 15 | $323.90 | |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 72 | $270.50 |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | <1% | 47 | $204.81 |
| 84479 | <1% | 143 | $97.97 | |
| 90682 | <1% | 16 | $89.75 | |
| J0702 | Injection, betamethasone acetate 3 mg and betamethasone sodium phosphate 3 mg | <1% | 17 | $68.00 |
| 82962 | <1% | 51 | $57.06 | |
| J3301 | Injection, triamcinolone acetonide, not otherwise specified, 10 mg | <1% | 12 | $45.20 |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 45 | $41.94 |
| J3420 | Injection, vitamin b-12 cyanocobalamin, up to 1000 mcg | <1% | 62 | $40.09 |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | <1% | 155 | $23.29 |
| 86141 | <1% | 43 | $11.99 | |
| J2704 | Injection, propofol, 10 mg | <1% | 16 | $1.40 |
| 3008F | <1% | 10,492 | $0.10 | |
| 1125F | <1% | 602 | $0.01 | |
| 3075F | 0% | 455 | $0.00 | |
| 3079F | 0% | 1,221 | $0.00 | |
| 3074F | 0% | 563 | $0.00 | |
| 3080F | 0% | 186 | $0.00 | |
| 3077F | 0% | 558 | $0.00 | |
| 1159F | 0% | 340 | $0.00 | |
| 3078F | 0% | 418 | $0.00 | |
| 888888 | 0% | 56 | $0.00 | |
| H0050 | Alcohol and/or drug services, brief intervention, per 15 minutes | 0% | 213 | $0.00 |
| 90785 | 0% | 33 | $0.00 | |
| 82977 | 0% | 26 | $0.00 | |
| G2211 | Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's single, serious condition or a complex condition. (add-on code, list separately in addition to office/outpatient evaluation and management visit, new or established) | 0% | 62 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialNALLEY, JOSEPH (CEO)
| Provider | Location | Paid |
|---|---|---|
| Kentucky Mental Health Care, L.L.C. | Louisville, KY | $5.66M |
| Kentucky Recovery Limited Liability Company | Louisville, KY | $2.78M |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.